Eur Rev Med Pharmacol Sci 2017; 21 (19): 4292-4297

Study on the correlation between CD14 gene polymorphism and susceptibility to laryngeal cancer

J. Su, J. Cui, H.-T. Xue, J.-H. Tian, J.-H. Zhang

Department of Otorhinolaryngology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China. xhtxht2000@sohu.com


OBJECTIVE: CD14 is the cell surface glycoprotein, which plays an important role in the occurrence and development of tumors. This study was designed to assess the association between CD14 SNPs and laryngeal cancer risk.

PATIENTS AND METHODS: This case-control study including 406 cases of laryngeal cancer and 893 healthy controls. The relationship between the genetic variation of CD14, rs2569190 and rs5744455, and the onset risk of laryngeal cancer were investigated. Logistic regression analysis was used to calculate the odds ratio (OR) and 95% confidence interval (CI) to study the relationship between CD14 gene polymorphism and pathogenesis of laryngeal cancer.

RESULTS: The results showed that rs5744455 mutation could increase the onset risk of laryngeal cancer (TT vs. CC: OR = 1.20, 95% CI = 1.01-1.41; additive model: OR = 1.20, 95% CI = 1.01-1.42). The results of stratified analysis showed that rs5744455 was associated with the susceptibility to laryngeal cancer in the elderly, females, non-smokers and non-drinkers (OR = 1.32, 95% CI = 1.04-1.66; OR = 1.58, 95% CI = 1.21-2.06; OR = 1.35, 95% CI = 1.08-1.69; OR = 1.31, 95% CI = 1.05-1.65). The analysis of combined effect of rs2569190 and rs5744455 showed that there was a combined effect between the two mutant loci (ptrend = 0.011).

CONCLUSIONS: This study suggested that the genetic variation of CD14, rs5744455, is related to the susceptibility to laryngeal cancer, providing a theoretical basis for the study of the pathogenesis of laryngeal cancer.

Free PDF Download

To cite this article

J. Su, J. Cui, H.-T. Xue, J.-H. Tian, J.-H. Zhang
Study on the correlation between CD14 gene polymorphism and susceptibility to laryngeal cancer

Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 19
Pages: 4292-4297